C12N 2310/3513
Protein
Official title: Protein; Peptide
C12N2310/3513 (Protein) appears on 673 US grants and 1,292 published applications in this corpus.
Search patents in C12N- Granted patents
- 673
- Published applications
- 1,292
- Assignees
- 455
- Inventors
- 1,927
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1997 | 12 | 0 |
| 1998 | 10 | 0 |
| 1999 | 7 | 0 |
| 2000 | 10 | 0 |
| 2001 | 4 | 2 |
| 2002 | 12 | 6 |
| 2003 | 6 | 18 |
| 2004 | 1 | 14 |
| 2005 | 2 | 15 |
| 2006 | 2 | 17 |
| 2007 | 4 | 17 |
| 2008 | 2 | 14 |
| 2009 | 3 | 23 |
| 2010 | 7 | 29 |
| 2011 | 16 | 29 |
| 2012 | 15 | 30 |
| 2013 | 23 | 25 |
| 2014 | 19 | 42 |
| 2015 | 30 | 61 |
| 2016 | 38 | 73 |
| 2017 | 35 | 57 |
| 2018 | 39 | 66 |
| 2019 | 40 | 68 |
| 2020 | 43 | 67 |
| 2021 | 49 | 108 |
| 2022 | 48 | 91 |
| 2023 | 49 | 120 |
| 2024 | 57 | 121 |
| 2025 | 59 | 106 |
| 2026 | 31 | 73 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Muscle-targeting complexes and uses thereof22 Sep 2026US 12,742,007 B2Dyne Therapeutics, Inc.
- Arc protein extracellular vesicle nucleic acid delivery platform1 Sep 2026US 12,723,246 B2University of Massachusetts
- RNAi constructs for inhibiting ASGR1 expression and methods of use thereof1 Sep 2026US 12,723,248 B1Amgen Inc.
- Polynucleotide conjugates comprising PLN-targeting anti-transferrin receptor antibodies and method of use thereof to treat PLN-associated cardiomyopathies18 Aug 2026US 12,708,669 B2Atrium Therapeutics, Inc.
- Muscle targeting complexes and formulations for treating myotonic dystrophy4 Aug 2026US 12,697,394 B2Dyne Therapeutics, Inc.
- Methods of minimising effects of smoke exposure8 Oct 2026US 2026/0308597 A1Rage Biotech Pty Ltd
- Nucleic acid-peptide-nucleic acid conjugate molecules and methods of making the same1 Oct 2026US 2026/0295069 A1Arizona Board of Regents on behalf of Arizona State University
- Compositions, systems and methods for programming immune cell function through targeted gene regulation1 Oct 2026US 2026/0297545 A1Duke University
- Alk7 rna interference agents1 Oct 2026US 2026/0297588 A1Eli Lilly and Company
- Pde3b rna interference agents1 Oct 2026US 2026/0297590 A1Eli Lilly and Company
Most cited
By later US patents
- 2'deoxy-2'-alkylnucleotide containing nucleic acid521US 5,627,053 ARibozyme Pharmaceuticals, Inc. · 1997
- Site specific delivery of nucleic acids by combining targeting ligands with endosomolytic components256US 9,345,780 B2Tekmira Pharmaceuticals Corporation · 2016
- Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof212US 6,589,940 B1Dynavax Technologies Corporation · 2003
- RNA-directed DNA cleavage by the Cas9-crRNA complex196US 9,637,739 B2Vilnius University · 2017
- Antisense modulation of CD40 expression173US 7,745,609 B2Isis Pharmaceuticals, Inc. · 2010